Assessing the impact of a novel house design on the incidence of malaria in children in rural Africa: study protocol for a household-cluster randomized controlled superiority trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
20 Jun 2022
Historique:
received: 15 01 2022
accepted: 09 06 2022
entrez: 20 6 2022
pubmed: 21 6 2022
medline: 23 6 2022
Statut: epublish

Résumé

Traditional rural housing in hot, humid regions of sub-Saharan Africa usually consists of single-level, poorly ventilated dwellings. Houses are mostly poorly screened against malaria mosquitoes and limited airflow discourages the use of bednets resulting in high indoor transmission. This study aims to determine whether living in a novel design house with elevated bedrooms and permeable screened walls reduces malaria, respiratory tract infections, and diarrhoea among children in rural Tanzania. This is a household-randomized, controlled study in 60 villages in Mtwara, Tanzania. A total of 550 households are randomly selected, 110 of which are allocated a novel design house and 440 households continue to reside in traditional houses. A dynamic cohort of about 1650 children under 13 years will be enrolled and followed for 3 years, approximately 330 living in novel design houses and 1320 in traditional rural houses. The primary endpoint is the incidence of malaria; secondary endpoints are incidences of acute respiratory tract infections and diarrhoea diseases detected by passive and active surveillance. Exposure to malaria vectors will be assessed using light traps in all study houses. Structural, economic, and social science studies will assess the durability, cost-effectiveness, and acceptability of the new houses compared with traditional housing. Environmental data will be collected indoors and outdoors in study homes to assess the differences between house typologies. This is the first randomized controlled trial to assess the protective efficacy of a new house design targeting malaria in sub-Saharan Africa. The findings of this study could influence the future construction of homes in hot and humid zones of Africa. ClinicalTrials.gov NCT04529434 . Registered on August 27, 2020.

Sections du résumé

BACKGROUND BACKGROUND
Traditional rural housing in hot, humid regions of sub-Saharan Africa usually consists of single-level, poorly ventilated dwellings. Houses are mostly poorly screened against malaria mosquitoes and limited airflow discourages the use of bednets resulting in high indoor transmission. This study aims to determine whether living in a novel design house with elevated bedrooms and permeable screened walls reduces malaria, respiratory tract infections, and diarrhoea among children in rural Tanzania.
METHODS/STUDY DESIGN METHODS
This is a household-randomized, controlled study in 60 villages in Mtwara, Tanzania. A total of 550 households are randomly selected, 110 of which are allocated a novel design house and 440 households continue to reside in traditional houses. A dynamic cohort of about 1650 children under 13 years will be enrolled and followed for 3 years, approximately 330 living in novel design houses and 1320 in traditional rural houses. The primary endpoint is the incidence of malaria; secondary endpoints are incidences of acute respiratory tract infections and diarrhoea diseases detected by passive and active surveillance. Exposure to malaria vectors will be assessed using light traps in all study houses. Structural, economic, and social science studies will assess the durability, cost-effectiveness, and acceptability of the new houses compared with traditional housing. Environmental data will be collected indoors and outdoors in study homes to assess the differences between house typologies.
DISCUSSION CONCLUSIONS
This is the first randomized controlled trial to assess the protective efficacy of a new house design targeting malaria in sub-Saharan Africa. The findings of this study could influence the future construction of homes in hot and humid zones of Africa.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT04529434 . Registered on August 27, 2020.

Identifiants

pubmed: 35725486
doi: 10.1186/s13063-022-06461-z
pii: 10.1186/s13063-022-06461-z
pmc: PMC9207857
doi:

Substances chimiques

Insecticides 0

Banques de données

ClinicalTrials.gov
['NCT04529434']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

519

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

Ann Am Thorac Soc. 2014 Jul;11(6):915-24
pubmed: 24960156
Bull World Health Organ. 1989;67(5):535-42
pubmed: 2692869
BMC Med Res Methodol. 2016 Mar 08;16:29
pubmed: 26956373
J R Soc Interface. 2021 May;18(178):20201030
pubmed: 33975463
Lancet Glob Health. 2018 Mar;6(3):e302-e315
pubmed: 29396217
BMC Microbiol. 2020 Jul 3;20(1):192
pubmed: 32620076
BMC Public Health. 2017 Nov 7;17(Suppl 4):776
pubmed: 29143638
J R Soc Interface. 2021 May;18(178):20210256
pubmed: 34034532
Malar J. 2015 Jun 09;14:209
pubmed: 26055986
Malar J. 2011 Apr 11;10:83
pubmed: 21477376
Acta Trop. 2018 May;181:84-94
pubmed: 29452110
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
Curr Opin Gastroenterol. 2016 Jan;32(1):18-23
pubmed: 26574867
PLOS Glob Public Health. 2021 Dec 7;1(12):e0000014
pubmed: 35211700
Lancet Glob Health. 2018 Mar;6(3):e316-e329
pubmed: 29396219
Rev Environ Health. 2021 Feb 03;36(3):297-307
pubmed: 33544536
Bull World Health Organ. 2008 May;86(5):390-398C
pubmed: 18545742
Malar J. 2016 Feb 24;15:110
pubmed: 26911145
Trans R Soc Trop Med Hyg. 1996 Sep-Oct;90(5):519-21
pubmed: 8944260
Malar J. 2003 Dec 10;2(1):45
pubmed: 14667242
Malar J. 2012 Jun 15;11:200
pubmed: 22704585
Lancet Planet Health. 2017 Aug;1(5):e188-e199
pubmed: 29851640
Malar J. 2020 Sep 19;19(1):341
pubmed: 32950061
Lancet Glob Health. 2019 Jan;7(1):e132-e147
pubmed: 30554749
Am J Trop Med Hyg. 1993 Oct;49(4):520-9
pubmed: 8214283
BMC Med. 2019 Aug 28;17(1):173
pubmed: 31462230
Lancet. 2009 Sep 19;374(9694):998-1009
pubmed: 19732949
PLoS Med. 2017 Feb 21;14(2):e1002234
pubmed: 28222094
Trop Med Int Health. 2020 Dec;25(12):1441-1449
pubmed: 32985048
Trans R Soc Trop Med Hyg. 2001 Sep-Oct;95(5):457-62
pubmed: 11706649
PLoS One. 2021 Nov 15;16(11):e0257689
pubmed: 34780482
Lancet Planet Health. 2021 Apr;5(4):e220-e229
pubmed: 33838737
Int J Epidemiol. 2016 Dec 1;45(6):2089-2099
pubmed: 27818376
Nature. 2019 Apr;568(7752):391-394
pubmed: 30918405

Auteurs

Salum Mshamu (S)

CSK Research Solutions, Mtwara, Tanzania.
Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

Arnold Mmbando (A)

Ifakara Health Institute, Ifakara, Tanzania.
Department of Biosciences, Durham University, Durham, UK.

Judith Meta (J)

University of Amsterdam, Amsterdam, Netherlands.

John Bradley (J)

MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.

Thomas Chevalier Bøjstrup (TC)

The Royal Danish Academy of Fine Arts, Copenhagen, Denmark.

Nicholas P J Day (NPJ)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand.

Mavuto Mukaka (M)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand.

Fredros Okumu (F)

Ifakara Health Institute, Ifakara, Tanzania.

Ally Olotu (A)

Ifakara Health Institute, Ifakara, Tanzania.

Christopher Pell (C)

University of Amsterdam, Amsterdam, Netherlands.

Jacqueline Deen (J)

University of Philippines, Manila, Philippines.

Jakob Knudsen (J)

The Royal Danish Academy of Fine Arts, Copenhagen, Denmark.

Steven W Lindsay (SW)

Department of Biosciences, Durham University, Durham, UK.

Lorenz von Seidlein (L)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. lorenz@tropmedres.ac.
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand. lorenz@tropmedres.ac.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH